C07K 14/522
Alpha-chemokines
Official title: {Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC}
C07K14/522 (Alpha-chemokines) appears on 193 US grants and 227 published applications in this corpus.
Search patents in C07K- Granted patents
- 193
- Published applications
- 227
- Assignees
- 169
- Inventors
- 528
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 4 | 0 |
| 1994 | 4 | 0 |
| 1995 | 9 | 0 |
| 1996 | 5 | 0 |
| 1997 | 7 | 0 |
| 1998 | 15 | 0 |
| 1999 | 10 | 0 |
| 2000 | 11 | 0 |
| 2001 | 1 | 1 |
| 2002 | 10 | 7 |
| 2003 | 4 | 16 |
| 2004 | 3 | 5 |
| 2005 | 5 | 7 |
| 2006 | 5 | 10 |
| 2007 | 4 | 7 |
| 2008 | 6 | 10 |
| 2009 | 2 | 9 |
| 2010 | 3 | 10 |
| 2011 | 6 | 9 |
| 2012 | 4 | 4 |
| 2013 | 3 | 6 |
| 2014 | 4 | 5 |
| 2015 | 4 | 5 |
| 2016 | 2 | 10 |
| 2017 | 3 | 5 |
| 2018 | 5 | 9 |
| 2019 | 6 | 12 |
| 2020 | 8 | 14 |
| 2021 | 4 | 7 |
| 2022 | 5 | 12 |
| 2023 | 6 | 11 |
| 2024 | 3 | 11 |
| 2025 | 7 | 12 |
| 2026 | 6 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for reducing elevated glucose levels11 Aug 2026US 12,703,856 B2SDF BioPharma Inc.
- Methods and compositions for treating cancer with von Willebrand factor peptide linked to immunotherapeutic antibodies11 Aug 2026US 12,706,227 B2The University of Chicago
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- CXCR3 ligand12 May 2026US 12,624,077 B2Chugai Seiyaku Kabushiki Kaisha
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications5 May 2026US 12,617,872 B2Xencor, Inc.
- Recombinant aav as an immune adjuvant24 Sep 2026US 2026/0285929 A1University of Florida Research Foundation, Inc.
- Cxcr3 ligand30 Jul 2026US 2026/0217779 A1Chugai Seiyaku Kabushiki Kaisha
- Methods for treating renal cell carcinoma30 Jul 2026US 2026/0217827 A1Corvus Pharmaceuticals, Inc.
- Multi-functional fusion proteins and uses thereof9 Jul 2026US 2026/0193312 A1Thomas Jefferson University
- Heterodimeric human igg1 polypeptides with isoelectric point modifications4 Jun 2026US 2026/0152576 A1Xencor, Inc.
Most cited
By later US patents
- Therapeutic interleukin-2-antibody based fusion proteins170US 5,314,995 AOncogen · 1994
- Modified PF4 compositions and methods of use156US 5,112,946 ARepligen Corporation · 1992
- Use of the cytokine IP-10 as an anti-tumor agent91US 5,474,981 APresident and Fellows of Harvard College · 1995
- Therapeutic antibody based fusion proteins91US 5,645,835 AOncogen · 1997
- Assays and therapeutic methods based on lymphocyte chemoattractants88US 5,514,555 ACenter for Blood Research, Inc. · 1996